Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...
Psychologists have long known that social situations profoundly influence human behavior, yet have lacked a unified, ...
Positions Combined Company to Lead in AI InfrastructureAcceptance Period Commences Today and Ends on May 9, 2026Rumble Has Secured Commitments ...
PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results